脑蛋白水解物(Cerebroprotein Hydrolysate) - 药物靶点：TNF-α_在研适应症：创伤性脑损伤，血管性痴呆，阿尔茨海默症_专利_临床

概要

基本信息

药物类型

化学药

别名

Cerebrolysin

+ [4]

靶点

TNF-α

作用方式

抑制剂、刺激剂

作用机制

TNF-α抑制剂(肿瘤坏死因子α抑制剂)、神经元刺激剂

治疗领域

神经系统疾病心血管疾病其他疾病+ [1]

在研适应症

创伤性脑损伤血管性痴呆阿尔茨海默症+ [4]

非在研适应症

急性缺血性卒中慢性脑血管意外

原研机构

EBEWE Pharma Ges.m.b.H. Nfg.KG

在研机构

EVER Neuro Pharma GmbHEBEWE Pharma Ges.m.b.H. Nfg.KG

非在研机构-

最高研发阶段批准上市

首次获批日期

奥地利 (1998-02-03),

脑卒中

最高研发阶段(中国)撤市

特殊审评-

登录后查看时间轴

关联

54

项与脑蛋白水解物相关的临床试验

NCT06489925

/ Not yet recruiting早期临床1期IIT

Cerebrolysin as an Add-On Therapy to Standard Treatment of Posterior Circulation Stroke Secondary to Basilar Artery Occlusion

The standard therapy for acute ischemic posterior circulation stroke (PCS) often leads to poor functional outcomes and high mortality rates, despite all advances in reperfusion therapy. Recent trials have shown that adding Cerebrolysin, a cerebral neuroprotective agent, to standard therapy for patients with acute ischemic anterior circulation stroke is safe and leads to improved functional outcomes. The purpose of this study is to assess the effectiveness and safety of Cerebrolysin with standard treatment for patients with PCS secondary to basilar artery occlusion (BAO).
The plan is to conduct a prospective, single-center, single-arm, open-label study with 20 acute basilar artery occlusion patients and premorbid modified Rankin Score (mRS) ≤3, treated with standard treatment (mechanical thrombectomy ± intravenous alteplase or conservative treatment) and Cerebrolysin as add-on therapy, compared with historical controls. Besides standard acute stroke assessment, standard treatment, and rehabilitation, the participants who meet the eligibility criteria will receive Cerebrolysin in a single-day dosage of 30 ml intravenously for 14 consecutive days. The participants will be closely monitored, and neuroimaging findings and clinical outcomes will be obtained during the drug administration period, on discharge, one month, and 3 months after the treatment onset.
The primary endpoints are mRS (0-3) on day 90 and mortality rate 90 days after the stroke onset. The secondary endpoints are defined as a change in any type of intracerebral bleeding and a change of min. 2 points on the National Institutes of Health Stroke Scale 24 hours, 14 days, 30 days, and 90 days post-stroke.
The investigators hypothesize that adding Cerebrolysin to standard stroke treatment will improve clinical outcomes and reduce morbidity and mortality in patients with acute basilar occlusion compared to standard treatment alone.

开始日期2024-07-01

申办/合作机构

EVER Neuro Pharma GmbH

NCT06339411

/ Not yet recruiting早期临床1期IIT

Examining the Efficacy of Cerebrolysin-Augmented Extended Time Window Thrombectomy in Acute Ischemic Stroke: An In-depth Study of Blood-brain Barrier Biomarkers and Imaging Indicators

Background:
Stroke is a leading cause of mortality and disability globally, with acute ischemic strokes(AIS) due to Large Vessel Occlusion (LVO) presenting significant treatment challenges. Mechanical thrombectomy (MT) has emerged as an effective intervention for AIS within an 8-hour window from symptom onset. However, the potential to extend this window up to 24 hours for select patients could revolutionize outcomes for those arriving late at comprehensive stroke centers. This study investigates the efficacy and safety of Cerebrolysin as an adjunct therapy to MT in extended time window and improving patient recovery.
Methods:
We conducted a multi-center, prospective, randomized study within the Chang Gung Memorial Hospital system in Taiwan, targeting 100 AIS patients eligible for MT beyond the traditional 8-hour window. Participants were randomized to receive either standard care or Cerebrolysin post-MT, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.
Results:
The primary outcome will measure the proportion of patients achieving favorable functional outcomes (modified Rankin Scale 0-2) at 90 days. Secondary outcomes include the impact of Cerebrolysin on secondary hemorrhagic transformation, brain edema, mortality rates, and quality of life. The study aims to provide comprehensive data on the benefits of adding Cerebrolysin to the standard post-MT care, focusing on its potential to protect against reperfusion injuries and maintain blood-brain barrier integrity.
Conclusion:
By evaluating the role of Cerebrolysin in conjunction with MT, this study aims to extend the therapeutic window for AIS treatment, offering hope for improved outcomes for patients who would otherwise be ineligible for current reperfusion therapies. The findings may pave the way for new guidelines in stroke management, emphasizing the importance of integrated care approaches in enhancing patient recovery.

开始日期2024-05-01

申办/合作机构

Chang Gung Memorial Hospital

ISRCTN45191532

/ RecruitingN/AIIT

CINEMA study - cerebrolysin neuro modulation Azerbaijan

开始日期2024-03-01

申办/合作机构

Azerbaijan Medical University

100 项与脑蛋白水解物相关的临床结果

登录后查看更多信息

100 项与脑蛋白水解物相关的转化医学

登录后查看更多信息

100 项与脑蛋白水解物相关的专利（医药）

登录后查看更多信息

546

项与脑蛋白水解物相关的文献（医药）

2025-12-01·Current Allergy and Asthma Reports

Treatment of COVID-19 Associated Olfactory Dysfunction: A Systematic Review

Review

作者: Vanderbroek, Annabelle ; Clijsters, Marnick ; Moyaert, Mathilde ; Van Gerven, Laura ; Bischoff, Sabrina

PURPOSE OF REVIEWCOVID -19 associated olfactory dysfunction is widespread, yet effective treatment strategies remain unclear. This article aims to provide a comprehensive systematic review of therapeutic approaches and offers evidence-based recommendations for their clinical application.RECENT FINDINGSA living Cochrane review, with rigorous inclusion criteria, has so far included 2 studies with a low certainty of evidence. In this systematic review we list clinical data of 36 randomised controlled trials (RCTs) and non-randomised studies published between Jan 1, 2020 and Nov 19, 2023 regarding treatment options for COVID-19 associated olfactory dysfunction. Nine treatment groups were analysed, including olfactory training, local and systemic corticosteroids, platelet-rich plasma (PRP), calcium chelators, vitamin supplements including palmitoylethanolamide with luteolin, insulin, gabapentin and cerebrolysin. Primary objective was the effect of the studied treatments on the delta olfactory function score (OFS) for objective/psychophysical testing. Treatments such as PRP and calcium chelators demonstrated significant improvements on OFS, whereas olfactory training and corticosteroids did not show notable efficacy for COVID-19 associated olfactory dysfunction.

2025-04-01·Neural Regeneration Research

Astrocytes, reactive astrogliosis, and glial scar formation in traumatic brain injury

Article

作者: Cieri, María Belén ; Ramos, Alberto Javier

Traumatic brain injury is a global health crisis, causing significant death and disability worldwide. Neuroinflammation that follows traumatic brain injury has serious consequences for neuronal survival and cognitive impairments, with astrocytes involved in this response. Following traumatic brain injury, astrocytes rapidly become reactive, and astrogliosis propagates from the injury core to distant brain regions. Homeostatic astroglial proteins are downregulated near the traumatic brain injury core, while pro-inflammatory astroglial genes are overexpressed. This altered gene expression is considered a pathological remodeling of astrocytes that produces serious consequences for neuronal survival and cognitive recovery. In addition, glial scar formed by reactive astrocytes is initially necessary to limit immune cell infiltration, but in the long term impedes axonal reconnection and functional recovery. Current therapeutic strategies for traumatic brain injury are focused on preventing acute complications. Statins, cannabinoids, progesterone, beta-blockers, and cerebrolysin demonstrate neuroprotective benefits but most of them have not been studied in the context of astrocytes. In this review, we discuss the cell signaling pathways activated in reactive astrocytes following traumatic brain injury and we discuss some of the potential new strategies aimed to modulate astroglial responses in traumatic brain injury, especially using cell-targeted strategies with miRNAs or lncRNA, viral vectors, and repurposed drugs.

2025-03-01·Behavioural Brain Research

Cerebrolysin treatment improved short-term memory deficits while simultaneously increasing hippocampal spine density in hypertensive female rats

Article

作者: Gómez-Villalobos, Ma de Jesús ; Morales-Medina, Julio César ; Espinoza, Ivette ; Aguilar-Hernández, Leonardo ; Flores, Gonzalo

Hypertension, if untreated, can disrupt the blood-brain-barrier (BBB) and reduce cerebral flow in the central nervous system (CNS) inducing hippocampal atrophy, potentially leading to cognitive deficits and vascular dementia. Spontaneous hypertensive rats (SHR) demonstrated neuroplastic alterations in the hippocampus, hyperlocomotion and memory deficits in males. Cerebrolysin (CBL), a neuropeptide preparation, induces synaptic and neuronal plasticity in various populations of neurons and repairs the integrity of the BBB. This research aims to investigate the behavioral outcomes in locomotion and recognition memory in the Novel Object Recognition Test (NORT) and assess the neuroreparative effect of CBL on the cytoarchitecture of neurons and the spine density in pyramidal neurons of the prefrontal cortex (PFC), the entorhinal cortex (EC) and the CA1 region of the dorsal hippocampus, as well as spheroidal neurons of the dentate gyrus (DG). Our findings indicate that SHR exhibited elevated diastolic and systolic pressures, and increased locomotion. Importantly, CBL treatment improved recognition memory in SHR strain. Hypertension led to reduced arborization in the EC, CA1, and DG regions. Moreover, CBL treatment increased arborization in both normotensive and hypertensive rats in the CA1, and DG regions of hippocampus and EC and selectively increased spine density in the hippocampus of hypertensive rats. These findings suggest that CBL neurotrophic treatment enhances recognition memory and promotes dendritic growth or spine density, depending on the neurochemical environment within the brain.

6

项与脑蛋白水解物相关的新闻（医药）

2025-01-09

·思齐俱乐部

200多个药退出市场！竞争格局生变

1月3日，国家药监局发布《关于注销颠茄磺苄啶片药品注册证书的公告(2025年第2号)》。公告显示，经评价，国家药品监督管理局决定自即日起停止颠茄磺苄啶片在我国的生产、销售、使用，注销药品注册证书。已上市销售的产品，由药品上市许可持有人负责召回，召回产品由所在地省级药品监督管理部门监督销毁或者依法采取其他无害化处理等措施。此次共涉及80个颠茄磺苄啶片被停止生产、销售、使用。涉及企业包括乐声药业石家庄有限公司、江中药业股份有限公司、石家庄四药有限公司、石家庄格瑞药业有限公司、邯郸市柏林药业有限公司、河北永丰药业有限公司、国药集团武汉中联四药药业有限公司、江苏恩华药业股份有限公司、江西鸿烁制药有限责任公司、华北制药河北华诺有限公司、河北恒利集团制药股份有限公司等。此外，2024年12月2日国家药监局还发布关于注销颠茄磺苄啶片等58个药品注册证书的公告(2024年第148号)，其中，11个颠茄磺苄啶片被注销药品注册证书。资料显示，颠茄磺苄啶片为抗菌药物，别名为泻立停，在注销之前可用于治疗痢疾杆菌引起的急慢性菌痢以及其他敏感致病菌引起的肠炎。业内表示，随着颠茄磺苄啶片的退市，相关市场的竞争格局或将发生变化。如在治疗腹泻方面，蒙脱石散等药品也有一定的作用，该药物是止泻药、肠道抗炎/抗感染药重要产品之一。据悉，当前关于“蒙脱石散”的批文有44条，涉及山东罗欣乐康制药、海南先声药业、浙江康恩贝制药等。据悉，根据《中华人民共和国药品管理法》第八十三条等有关规定，经评价，对疗效不确切、不良反应大或者因其他原因危害人体健康的药品，应当注销药品注册证书。已被注销药品注册证书的药品，不得生产或者进口、销售和使用。根据数据统计，在刚刚过去的2024年全年，共有145个药品被注销注册证书。如根据国家药监局关于注销颠茄磺苄啶片等58个药品注册证书的公告(2024年第148号)，除了11个颠茄磺苄啶片被注销药品注册证书外，还包括3个氯沙坦钾片、2个安乃近片、2个苯磺酸氨氯地平片、2个恩替卡韦片、2个复方蛇胆川贝散、2个利福平胶囊等。根据2024年4月11日，国家药监局关于注销泛影葡胺注射液等87个药品注册证书的公告(2024年第43号)，注销注册证书的药品包括泛影葡胺注射液、阿德福韦酯片、氟康唑氯化钠注射液、甘露醇注射液、注射用氨苄西林钠、盐酸小檗碱片、维生素C片、盐酸多西环素片、呋喃唑酮片、碘佛醇注射液、甘精胰岛素注射液、地特胰岛素注射液、盐酸伐地那非片、脑蛋白水解物注射液等。药品注册证书是药品生产、进口、销售和使用的重要法律依据，一旦药品注册证书被注销，该药品就失去了在市场上合法流通的资。根据统计，2024年至今，共有225个药品退出市场。来源：制药网作者：药机君商务合作 130 6172 3098 zakk.cui@siqibest.com 点击阅读原文了解更多

一致性评价

2025-01-08

·思齐俱乐部

225个药品退出市场！相关市场竞争格局或将生变

1月3日，国家药监局发布《关于注销颠茄磺苄啶片药品注册证书的公告(2025年第2号)》。公告显示，经评价，国家药品监督管理局决定自即日起停止颠茄磺苄啶片在我国的生产、销售、使用，注销药品注册证书。已上市销售的产品，由药品上市许可持有人负责召回，召回产品由所在地省级药品监督管理部门监督销毁或者依法采取其他无害化处理等措施。此次共涉及80个颠茄磺苄啶片被停止生产、销售、使用。涉及企业包括乐声药业石家庄有限公司、江中药业股份有限公司、石家庄四药有限公司、石家庄格瑞药业有限公司、邯郸市柏林药业有限公司、河北永丰药业有限公司、国药集团武汉中联四药药业有限公司、江苏恩华药业股份有限公司、江西鸿烁制药有限责任公司、华北制药河北华诺有限公司、河北恒利集团制药股份有限公司等。此外，2024年12月2日国家药监局还发布关于注销颠茄磺苄啶片等58个药品注册证书的公告(2024年第148号)，其中，11个颠茄磺苄啶片被注销药品注册证书。资料显示，颠茄磺苄啶片为抗菌药物，别名为泻立停，在注销之前可用于治疗痢疾杆菌引起的急慢性菌痢以及其他敏感致病菌引起的肠炎。业内表示，随着颠茄磺苄啶片的退市，相关市场的竞争格局或将发生变化。如在治疗腹泻方面，蒙脱石散等药品也有一定的作用，该药物是止泻药、肠道抗炎/抗感染药重要产品之一。据悉，当前关于“蒙脱石散”的批文有44条，涉及山东罗欣乐康制药、海南先声药业、浙江康恩贝制药等。据悉，根据《中华人民共和国药品管理法》第八十三条等有关规定，经评价，对疗效不确切、不良反应大或者因其他原因危害人体健康的药品，应当注销药品注册证书。已被注销药品注册证书的药品，不得生产或者进口、销售和使用。根据数据统计，在刚刚过去的2024年全年，共有145个药品被注销注册证书。如根据国家药监局关于注销颠茄磺苄啶片等58个药品注册证书的公告(2024年第148号)，除了11个颠茄磺苄啶片被注销药品注册证书外，还包括3个氯沙坦钾片、2个安乃近片、2个苯磺酸氨氯地平片、2个恩替卡韦片、2个复方蛇胆川贝散、2个利福平胶囊等。根据2024年4月11日，国家药监局关于注销泛影葡胺注射液等87个药品注册证书的公告(2024年第43号)，注销注册证书的药品包括泛影葡胺注射液、阿德福韦酯片、氟康唑氯化钠注射液、甘露醇注射液、注射用氨苄西林钠、盐酸小檗碱片、维生素C片、盐酸多西环素片、呋喃唑酮片、碘佛醇注射液、甘精胰岛素注射液、地特胰岛素注射液、盐酸伐地那非片、脑蛋白水解物注射液等。药品注册证书是药品生产、进口、销售和使用的重要法律依据，一旦药品注册证书被注销，该药品就失去了在市场上合法流通的资格。根据统计，2024年至今，共有225个药品退出市场。来源：制药网商务合作 130 6172 3098 zakk.cui@siqibest.com 点击阅读原文了解更多

一致性评价医药出海上市批准

2025-01-06

·赛柏蓝

225个药退出市场，涉大批知名药企（附名单）

作者 | 颜色来源 | 赛柏蓝停止生产、销售、使用，知名药品退市。 02 泻立停被停用涉大批厂家 “泻立停泻立停，痢疾拉肚，一吃就停。”近日，耳熟能详的泻立停被停用。 1月3日，国家药监局发布《关于注销颠茄磺苄啶片药品注册证书的公告（2025年第2号）》。颠茄磺苄啶片为抗菌药物，别名为泻立停。国家药监局决定自即日起停止颠茄磺苄啶片在我国的生产、销售、使用，注销药品注册证书。已上市销售的产品，由药品上市许可持有人负责召回，召回产品由所在地省级药品监督管理部门监督销毁或者依法采取其他无害化处理等措施。此次共涉及80个颠茄磺苄啶片被停止生产、销售、使用。此外，2024年12月2日，国家药监局还发布了关于注销颠茄磺苄啶片等58个药品注册证书的公告，其中，11个颠茄磺苄啶片被注销药品注册证书。国家药监局要求停止颠茄磺苄啶片在我国的生产、销售、使用，主要是依据《中华人民共和国药品管理法》第八十三条等有关规定，经评价，对疗效不确切、不良反应大或者因其他原因危害人体健康的药品，应当注销药品注册证书。已被注销药品注册证书的药品，不得生产或者进口、销售和使用。颠茄磺苄啶片为复方制剂，主要药效成分包括颠茄流浸膏、磺胺甲噁唑、甲氧苄啶等，可用于治疗痢疾杆菌引起的急慢性菌痢以及其他敏感致病菌引起的肠炎。目前，除泻立停外，蒙脱石散等药品也对治疗腹泻有一定作用。米内网数据显示，胃肠道疾病发病正呈现出高发性、普遍性及年轻化的趋势。2022年前三季度中国重点省市公立医院终端止泻药、肠道抗炎/抗感染销售额超过12亿元，同比增长6.30%。蒙脱石散在中国三大终端六大市场销售规模超过10亿元，其中，院外市场是主力销售渠道，同比增长60%，是止泻药、肠道抗炎/抗感染药Top 2产品。赛柏蓝在国家药监局官网搜索发现，关于“蒙脱石散”的批文有44条，涉及山东罗欣乐康制药、海南先声药业、浙江康恩贝制药等。随着颠茄磺苄啶片的退市，相关市场的竞争格局或将生变。 02 2024年已有145个药品退市药品注册证书是药品生产、进口、销售和使用的重要法律依据，一旦药品注册证书被注销，该药品就失去了在市场上合法流通的资格，不得再继续生产、进口、销售和使用。《药品注册管理办法》规定，具备以下情形之一的，由国家药监局注销药品注册证书，并予以公布：据赛柏蓝不完全统计，2024年共有145个药品被注销注册证书。 2024年12月2日，国家药监局发布《关于注销颠茄磺苄啶片等58个药品注册证书的公告》，注销注册证书的药品包括11个颠茄磺苄啶片、3个氯沙坦钾片、2个安乃近片、2个苯磺酸氨氯地平片、2个恩替卡韦片、2个复方蛇胆川贝散、2个利福平胶囊等。安乃近是吡唑酮类解热镇痛药，在我国上市时间较早，制剂种类包括口服制剂、注射剂、滴鼻液等。安乃近注射液、安乃近氯丙嗪注射液、小儿安乃近灌肠液、安乃近滴剂、安乃近滴鼻液、滴鼻用安乃近溶液片、小儿解热栓存在严重过敏反应、粒细胞缺乏症等严重不良反应，风险大于获益，且临床均有替代药品，已经在2020年被注销药品注册证书。安乃近片等口服制剂尚有一定临床价值，国家药监局对安乃近片、重感灵片、重感灵胶囊、复方青蒿安乃近片采取修订说明书的风险控制措施，增加安全警示信息，限制适用人群和适应症范围。在国内解热镇痛药物市场中，安乃近占比较低，并呈现不断减少的趋势。赛柏蓝在国家药监局官网搜索发现，关于“安乃近片”的批文有861条，涉及企业众多，竞争激烈。随着相关批文的药品被注销，这一市场将被继续分割。 2024年4月11日，根据《中华人民共和国药品管理法实施条例》和《药品注册管理办法》的有关规定，国家药监局决定注销泛影葡胺注射液等87个药品注册证书。赛柏蓝梳理发现，7个碘佛醇注射液、6个甘精胰岛素注射液、4个地特胰岛素注射液、4个盐酸伐地那非片、3个脑蛋白水解物注射液等被注销注册证书。注：文中统计的药品数未去重。附：国家药监局公布的2024年-截至目前注销的药品注册证书清单 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

上市批准一致性评价医药出海

100 项与脑蛋白水解物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	脑蛋白水解物	B05BA04	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
创伤性脑损伤	德国	EBEWE Pharma Ges.m.b.H. Nfg.KG	2000-01-01
血管性痴呆	德国	EBEWE Pharma Ges.m.b.H. Nfg.KG	2000-01-01
阿尔茨海默症	奥地利	EVER Neuro Pharma GmbH	1998-10-28
脑卒中	奥地利	EVER Neuro Pharma GmbH	1998-02-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床3期	斯洛伐克	EVER Neuro Pharma GmbH	2005-10-01
急性缺血性卒中	临床3期	斯洛文尼亚	EVER Neuro Pharma GmbH	2005-10-01
急性缺血性卒中	临床3期	奥地利	EVER Neuro Pharma GmbH	2005-10-01
急性缺血性卒中	临床3期	克罗地亚	EVER Neuro Pharma GmbH	2005-10-01
急性缺血性卒中	临床3期	捷克	EVER Neuro Pharma GmbH	2005-10-01
阿尔茨海默症	临床3期	中国	EVER Neuro Pharma GmbH	2005-02-04
慢性脑血管意外	临床前	奥地利	EVER Neuro Pharma GmbH	2021-06-25
脑损伤	临床前	西班牙	EVER Neuro Pharma GmbH	-
脑损伤	临床前	奥地利	EVER Neuro Pharma GmbH	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04830943 (Pubmed \| Expert Rev Clin Pharmacol)	临床3期	新冠肺炎后遗症	250	Cerebrolysin + olfactory and gustatory trainings	構獵壓鏇壓夢積醖襯夢(獵網獵築構夢鬱網選簾) = 夢獵齋鹹鹹餘壓醖窪構範鏇襯艱艱衊鬱憲網觸 (積艱糧夢積顧鬱廠網壓 ) 更多	积极	2023-12-02
Pubmed \| Neurol Sci	N/A	脑卒中	1,879	Cerebrolysin	蓋糧廠積遞糧積齋積艱(選網夢餘蓋願淵齋選襯): MW = 0.61 (95% CI, 0.52 ~ 0.69), P-Value = 0.0118	积极	2018-04-01
				Placebo
SFN2016	N/A	颅脑损伤	-	cerebrolysin (HA rats at simulated high altitude)	遞齋鹹衊鏇範鏇膚醖鏇(築獵膚齋憲願糧窪範窪) = 鬱鑰壓鹽廠鏇壓繭鹹範淵選蓋夢獵觸鏇淵製廠 (鬱獵製膚餘夢獵醖衊範 ) 更多	-	2016-11-14
NCT02149875 (CTgov)	临床1/2期	急性缺血性卒中	84	Dl-3-n-butylphthalide (Dl-3-n-butylphthalide)	蓋觸壓衊壓鏇醖鹽網糧(鏇構製艱鹹網觸選齋壓) = 膚顧艱蓋範繭積鏇襯糧鏇範衊積獵顧壓遞憲淵 (蓋範積築獵廠壓遞廠齋, 夢遞獵鹽齋鹹顧餘網製 ~ 夢憲獵醖廠壓鹽顧範廠) 更多	-	2016-05-18
				Cerebrolysin (Cerebrolysin)	蓋觸壓衊壓鏇醖鹽網糧(鏇構製艱鹹網觸選齋壓) = 衊製願餘膚齋壓醖積膚鏇範衊積獵顧壓遞憲淵 (蓋範積築獵廠壓遞廠齋, 鏇願襯積繭構夢齋窪製 ~ 獵願膚獵網願憲簾獵鑰) 更多
ISC2016	N/A	脑卒中	-	Cerebrolysin	餘獵鏇遞築選窪夢積蓋(蓋獵鑰簾繭鹹廠糧鹹鏇) = 鹽繭構鹹醖積選繭餘壓觸蓋範鬱願範衊鹹憲積 (築獵網齋淵鹹顧醖衊繭 )	-	2016-02-01
				Saline	餘獵鏇遞築選窪夢積蓋(蓋獵鑰簾繭鹹廠糧鹹鏇) = 壓艱鏇構鏇憲遞網窪鏇觸蓋範鬱願範衊鹹憲積 (築獵網齋淵鹹顧醖衊繭 )
SFN2013	N/A	-	-	cerebrolysin (Hypertensive rats at room temperature)	製築餘遞夢襯簾顧壓餘(襯蓋壓淵鹽蓋壓選淵鑰) = 淵選壓鹽衊鬱獵構鬱構鏇夢鹽窪壓網築獵鹹憲 (糧憲夢壓鏇製鏇餘蓋壓 ) 更多	-	2013-11-13
				cerebrolysin (Normotensive rats exposed to SiO2 NPs and SWCNT in combination with heat stress)	製築餘遞夢襯簾顧壓餘(襯蓋壓淵鹽蓋壓選淵鑰) = 醖窪齋憲簾淵範鏇獵積鏇夢鹽窪壓網築獵鹹憲 (糧憲夢壓鏇製鏇餘蓋壓 )
NCT00868283 (Pubmed \| Stroke)	临床4期	急性缺血性卒中	1,070	Cerebrolysin	網窪膚顧願願齋遞蓋鹹(範淵簾淵範糧積繭簾選) = 壓獵遞網艱壓鏇窪醖願糧淵衊餘築積齋淵襯築 (觸選網衊鹹憲鏇繭顧顧 )	-	2012-03-01
				Placebo	網窪膚顧願願齋遞蓋鹹(範淵簾淵範糧積繭簾選) = 築鏇鬱糧艱艱選鹹蓋餘糧淵衊餘築積齋淵襯築 (觸選網衊鹹憲鏇繭顧顧 )
Pubmed \| J Stroke Cerebrovasc Dis	N/A	血管性痴呆	-	Cerebrolysin 20 mL	(壓憲襯齋構獵鹹糧餘憲) = 壓積築積窪獵獵範鹹鑰鏇窪壓鏇鹽簾窪襯構鏇 (憲淵願簾顧選醖積顧齋 ) 更多	-	2011-07-01
				Placebo	(壓憲襯齋構獵鹹糧餘憲) = 鑰艱壓衊艱網築繭網遞鏇窪壓鏇鹽簾窪襯構鏇 (憲淵願簾顧選醖積顧齋 ) 更多
NCT00947531 (VascDem, CTgov)	临床4期	血管性痴呆	242	Cerebrolysin (Cerebrolysin)	網鹹鏇鑰艱淵膚築選齋(觸願衊鹹顧築壓顧夢襯) = 蓋遞製鏇製鑰構糧鬱醖觸繭餘襯壓廠膚構選簾 (壓繭構糧鹽壓簾構構膚, 淵觸網製膚醖衊願鹽夢 ~ 窪餘艱廠夢壓衊簾獵糧) 更多	-	2009-07-28
				0.9% Saline Solution (0.9% Saline Solution)	網鹹鏇鑰艱淵膚築選齋(觸願衊鹹顧築壓顧夢襯) = 顧築繭觸簾壓鏇艱網鏇觸繭餘襯壓廠膚構選簾 (壓繭構糧鹽壓簾構構膚, 觸遞醖糧艱觸淵艱鹹艱 ~ 鹹淵膚壓鹹顧醖襯廠積) 更多
AAIC2009	N/A	血管性痴呆追加	242	Cerebrolysin	構鑰觸憲築夢選簾遞鬱(鏇顧蓋構鏇憲壓膚鹹構) = 糧範簾願觸糧構夢憲繭醖積鹹鏇築艱夢範齋範 (齋鹽襯壓選顧鬱選網醖 ) 更多	积极	2009-07-01
				Placebo	構鑰觸憲築夢選簾遞鬱(鏇顧蓋構鏇憲壓膚鹹構) = 構糧窪顧窪鏇製鹽衊醖醖積鹹鏇築艱夢範齋範 (齋鹽襯壓選顧鬱選網醖 ) 更多